{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "source": [
        "%pip install -U langgraph langchain-tavily langgraph-checkpoint-sqlite"
      ],
      "metadata": {
        "id": "7-rcwm2VKU5a"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install openai"
      ],
      "metadata": {
        "id": "inSA0dckU5dJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install -U jupyter-client"
      ],
      "metadata": {
        "id": "w8yh_1ava8xr"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install -U langchain-openai"
      ],
      "metadata": {
        "id": "kQ1Es9aDVQp_"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from langgraph.prebuilt import create_react_agent"
      ],
      "metadata": {
        "id": "lgkhkXfgZJxf"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain_core.tools import tool"
      ],
      "metadata": {
        "id": "QkHzYvumafqZ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "\n"
      ],
      "metadata": {
        "id": "X0Cc6HXjUhQb"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pip install langchain pydantic requests\n"
      ],
      "metadata": {
        "id": "aFkW-w73ZZyL"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import time\n",
        "import re\n",
        "import requests\n",
        "from urllib.parse import urlparse, parse_qsl, urlencode, urlunparse\n",
        "from typing import List, Optional, Dict, Any\n",
        "from pydantic import BaseModel, Field\n",
        "from google.colab import userdata\n",
        "from langchain.tools import StructuredTool\n",
        "\n",
        "GOOGLE_CSE_API_KEY = userdata.get(\"GOOGLE_CSE\")\n",
        "GOOGLE_CSE_CX = userdata.get(\"GOOGLE_CSE_CX\")\n",
        "GOOGLE_CSE_ENDPOINT = \"https://www.googleapis.com/customsearch/v1\"\n",
        "\n",
        "# --- helpers ---\n",
        "def now_iso() -> str:\n",
        "    return time.strftime(\"%Y-%m-%dT%H:%M:%SZ\", time.gmtime())\n",
        "\n",
        "def canonicalize_url(url: str) -> str:\n",
        "    try:\n",
        "        parts = urlparse(url)\n",
        "        netloc = parts.netloc.lower().replace(\":80\",\"\").replace(\":443\",\"\")\n",
        "        q = [(k,v) for k,v in parse_qsl(parts.query) if not k.startswith(\"utm_\") and k not in {\"gclid\",\"fbclid\"}]\n",
        "        return urlunparse((parts.scheme, netloc, parts.path, parts.params, urlencode(q), parts.fragment))\n",
        "    except Exception:\n",
        "        return url\n",
        "\n",
        "class GoogleSearchInput(BaseModel):\n",
        "    query: str = Field(..., description=\"Web search query\")\n",
        "    k: int = Field(5, ge=1, le=10, description=\"Max results to return\")\n",
        "    safe: str = Field(\"active\", description=\"SafeSearch mode: active|off\")\n",
        "    lr: Optional[str] = Field(None, description=\"Language restrict, e.g. 'lang_en'\")\n",
        "\n",
        "def google_search(query: str, k: int = 5, safe: str = \"active\", lr: Optional[str] = None) -> List[Dict[str, Any]]:\n",
        "    if not GOOGLE_CSE_API_KEY or not GOOGLE_CSE_CX:\n",
        "        raise RuntimeError(\"Set GOOGLE_CSE_API_KEY and GOOGLE_CSE_CX env vars\")\n",
        "\n",
        "    params = {\n",
        "        \"key\": GOOGLE_CSE_API_KEY,\n",
        "        \"cx\": GOOGLE_CSE_CX,\n",
        "        \"q\": query,\n",
        "        \"num\": min(k, 10),\n",
        "        \"safe\": safe\n",
        "    }\n",
        "    if lr:\n",
        "        params[\"lr\"] = lr\n",
        "\n",
        "    resp = requests.get(GOOGLE_CSE_ENDPOINT, params=params, timeout=15)\n",
        "    resp.raise_for_status()\n",
        "    data = resp.json()\n",
        "\n",
        "    hits = []\n",
        "    for it in data.get(\"items\", []):\n",
        "        title = (it.get(\"title\") or \"\").strip()\n",
        "        url = canonicalize_url((it.get(\"link\") or \"\").strip())\n",
        "        snippet = (it.get(\"snippet\") or \"\").strip()\n",
        "        if not title or not url:\n",
        "            continue\n",
        "        snippet = re.sub(r\"\\s+\", \" \", snippet)\n",
        "        hits.append({\n",
        "            \"title\": title,\n",
        "            \"url\": url,\n",
        "            \"snippet\": snippet,\n",
        "            \"source\": \"google_cse\",\n",
        "            \"seen_at\": now_iso()\n",
        "        })\n",
        "    return hits[:k]\n",
        "\n",
        "GoogleSearchTool = StructuredTool.from_function(\n",
        "    func=google_search,\n",
        "    name=\"web_search\",\n",
        "    description=\"Search return {title,url,snippet,source,seen_at}.\",\n",
        "    args_schema=GoogleSearchInput\n",
        ")\n"
      ],
      "metadata": {
        "id": "75ma3eQRnsqC"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "if __name__ == \"__main__\":\n",
        "    results = GoogleSearchTool.invoke({\"query\": \"CRISPR gene editing 2023 review\", \"k\": 3})\n",
        "    for r in results:\n",
        "        print(r)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "34UVF8HgodZl",
        "outputId": "12eaeebc-576f-4143-d403-e0d3ab5e48b6"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'title': 'CRISPR/Cas9 therapeutics: progress and prospects | Signal ...', 'url': 'https://www.nature.com/articles/s41392-023-01309-7', 'snippet': 'Jan 16, 2023 ... This paper reviews the current developments in three aspects, namely, gene-editing type, delivery vector, and disease characteristics.', 'source': 'google_cse', 'seen_at': '2025-08-24T01:12:08Z'}\n",
            "{'title': 'Unintended CRISPR-Cas9 editing outcomes: a review of the ...', 'url': 'https://pubmed.ncbi.nlm.nih.gov/37093294/', 'snippet': '... editing applications. Here we review SVs associated with CRISPR-editing in cells of human origin and highlight the methods used to detect and avoid them. Â© 2023 ...', 'source': 'google_cse', 'seen_at': '2025-08-24T01:12:08Z'}\n",
            "{'title': 'Application of CRISPR-Cas9 genome editing technology in various ...', 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10916045/', 'snippet': 'Overall, CRISPR-Cas9 technology has revolutionized genome editing, providing researchers with a versatile and efficient tool for genetic modification. Its ...', 'source': 'google_cse', 'seen_at': '2025-08-24T01:12:08Z'}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.agents import initialize_agent, AgentType\n",
        "from langgraph.prebuilt import create_react_agent\n",
        "import openai\n",
        "\n",
        "user_input = input(\"What is your article about?\")\n",
        "\n",
        "perspectives = ['Molecular Biologist', 'Medical Researcher', 'Agricultural Scientist', 'Bioethicist', 'Regulatory Policy Expert', 'Basic Fact Researcher']\n",
        "\n",
        "ASKER = init_chat_model(\"gpt-4o-mini\", model_provider=\"openai\", openai_api_key=userdata.get(\"OPENAI_API_KEY\"))\n",
        "LLM_2 = init_chat_model(\"gpt-4.1\", model_provider=\"openai\", openai_api_key=userdata.get(\"OPENAI_API_KEY\"))\n",
        "tools = [GoogleSearchTool]\n",
        "EXPERT_RESEARCHER = create_react_agent(LLM_2, tools)\n",
        "\n",
        "convo = []\n",
        "M = 6\n",
        "for p in perspectives:\n",
        "  convo_history = []\n",
        "  for i in range(M):\n",
        "    query = f\"You are a Wikipedia Writer and you are writing an article on {user_input}, ask a question from the perspective of a {p} to contribute to further understanding of the topic based on the given conversation history between you and an expert: {convo_history}. Only respond with the question\"\n",
        "    q = ASKER.invoke([{\"role\": \"user\", \"content\": query}])\n",
        "    convo_history.append(q.content)\n",
        "    input_message = {\"role\": \"user\", \"content\": f\"Split the given query: {q} into Google searches in order to best answer the question, respond with at most 3 credible sources from the web\"}\n",
        "    a = EXPERT_RESEARCHER.invoke({\"messages\": [input_message]})\n",
        "    convo_history.append(a)\n",
        "\n",
        "  convo.append(convo_history)\n",
        "\n",
        "print(\"end\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eY9ftej-pxvi",
        "outputId": "27665671-7fdb-41cc-e604-a93710f07c0f"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "What is your article about?CRISPR\n",
            "end\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iqpnMsouvDLw",
        "outputId": "979af6d4-aa56-46ee-b3c0-b8ed862360ab"
      },
      "execution_count": 17,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "What is your article about? CRISPR\n",
            "\n",
            "=== Persona: Molecular Biologist ===\n",
            "[Molecular Biologist Asker] What are the most recent advancements in CRISPR technology for therapeutic applications?\n",
            "[Expert] Recent advancements in CRISPR technology for therapeutic applications include:\n",
            "\n",
            "- Expansion of CRISPR-based gene editing in clinical trials, with a notable shift in the CRISPR medicine landscape as of 2024. There is increased focus on refining delivery methods and improving safety and efficacy for human therapies (see Innovative Genomics).\n",
            "- Progress in using CRISPR/Cas9 for cancer immunotherapy, though challenges remain in clinical translation, such as immune response management and precise targeting (see EHO Online).\n",
            "- The use of CRISPR screens to identify new therapeutic targets, which is opening promising avenues for treatment, especially in oncology and genetic diseases (see Molecular Cancer).\n",
            "\n",
            "These developments highlight ongoing efforts to translate CRISPR technology into effective and safe therapies for a range of diseases.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR Clinical Trials: A 2024 Update - Innovative Genomics\", \"url\": \"https://innovativegenomics.org/news/crispr-clinical-trials-2024/\"},\n",
            "  {\"title\": \"CRISPR/Cas9 technology for advancements in cancer immunotherapy\", \"url\": \"https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00570-y\"},\n",
            "  {\"title\": \"Comprehensive review of CRISPR-based gene editing\", \"url\": \"https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01925-5\"}\n",
            "]\n",
            "[Molecular Biologist Asker] What specific challenges are being addressed in the clinical translation of CRISPR/Cas9 for cancer immunotherapy?\n",
            "[Expert] Specific challenges in the clinical translation of CRISPR/Cas9 for cancer immunotherapy include:\n",
            "\n",
            "1. Delivery: Efficient and targeted delivery of CRISPR/Cas9 components to tumor or immune cells remains a major barrier, with nanotechnology-based approaches being explored to improve this aspect.\n",
            "2. Off-target effects: Ensuring specificity and minimizing unintended gene edits is critical to avoid adverse effects and ensure safety.\n",
            "3. Immune response: The potential for immune reactions against CRISPR components or edited cells poses a risk for clinical applications.\n",
            "4. Tumor heterogeneity and resistance: The genetic diversity within tumors can limit the effectiveness of CRISPR-based therapies and lead to resistance.\n",
            "5. Regulatory and ethical considerations: Clinical translation is also challenged by regulatory hurdles and ethical concerns regarding gene editing in humans.\n",
            "\n",
            "These challenges are being actively researched to pave the way for safe and effective clinical use of CRISPR/Cas9 in cancer immunotherapy.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Advancements and Obstacles of CRISPR-Cas9 Technology in ...\", \"url\": \"https://www.sciencedirect.com/science/article/pii/S2329050119300282\"},\n",
            "  {\"title\": \"Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34324887/\"},\n",
            "  {\"title\": \"CRISPR/Cas9 system: recent applications in immuno-oncology and ...\", \"url\": \"https://ehoonline.biomedcentral.com/articles/10.1186/s40164-023-00457-4\"}\n",
            "]\n",
            "[Molecular Biologist Asker] What strategies are being developed to enhance the specificity and reduce off-target effects of CRISPR/Cas9 in cancer therapies?\n",
            "[Expert] Recent strategies to enhance the specificity and reduce off-target effects of CRISPR/Cas9 in cancer therapies include: extending the length of single guide RNA (sgRNA) to improve target recognition, engineering Cas9 variants with higher fidelity, and optimizing guide RNA design. Reviews also highlight the development of advanced delivery systems and improved detection methods for off-target mutations. These approaches collectively aim to increase the precision and safety of CRISPR-based cancer treatments.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Recent Advancements in Reducing the Off-Target Effect of CRISPR ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/\"},\n",
            "  {\"title\": \"Comprehensive review of CRISPR-based gene editing ...\", \"url\": \"https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01925-5\"},\n",
            "  {\"title\": \"Off-target Effects in CRISPR/Cas9-mediated Genome Engineering ...\", \"url\": \"https://www.sciencedirect.com/science/article/pii/S216225311630049X\"}\n",
            "]\n",
            "[Molecular Biologist Asker] What are the implications of off-target effects in the long-term safety and efficacy of CRISPR-based cancer therapies?\n",
            "[Expert] Off-target effects in CRISPR-based cancer therapies refer to unintended genetic modifications at sites other than the intended target. These effects have significant implications for both long-term safety and efficacy:\n",
            "\n",
            "- Safety: Off-target mutations can disrupt essential genes, including tumor suppressor genes, potentially leading to new malignancies or other adverse effects. This is a major concern for clinical applications, as even rare off-target events could have serious long-term consequences (see GenEngNews, Molecular Cancer).\n",
            "- Efficacy: Off-target effects may reduce the precision and potency of CRISPR therapies, potentially diminishing their therapeutic benefit or causing unpredictable biological outcomes (see ScienceDirect, Molecular Cancer).\n",
            "- Monitoring: Early clinical trials have shown low off-target activity and short-term safety, but long-term effects remain under observation. Ongoing research aims to improve CRISPR precision to mitigate these risks (see NCI, ScienceDirect).\n",
            "\n",
            "In summary, while CRISPR-based cancer therapies show promise, minimizing off-target effects is crucial to ensure their long-term safety and sustained efficacy.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Comprehensive review of CRISPR-based gene editing ...\", \"url\": \"https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01925-5\"},\n",
            "  {\"title\": \"Genetic Differences Could Impact Efficacy and Safety of CRISPR\", \"url\": \"https://www.genengnews.com/news/genetic-differences-could-impact-efficacy-and-safety-of-crispr/\"},\n",
            "  {\"title\": \"How CRISPR Is Changing Cancer Research and Treatment - NCI\", \"url\": \"https://www.cancer.gov/news-events/cancer-currents-blog/2020/crispr-cancer-research-treatment\"}\n",
            "]\n",
            "[Molecular Biologist Asker] What methods are being explored to monitor and assess off-target effects in patients undergoing CRISPR-based cancer therapies?\n",
            "[Expert] Several methods are being explored to monitor and assess off-target effects in patients undergoing CRISPR-based cancer therapies:\n",
            "\n",
            "1. High-throughput sequencing is widely used to detect and quantify off-target indels (insertions/deletions) at both predicted and unexpected genomic sites, providing a direct measure of editing activity (source: Cell, Molecular Therapy Nucleic Acids).\n",
            "2. In vivo detection methods are being developed to directly measure off-target effects in somatic cells, which is crucial for gene therapy applications (source: PMC).\n",
            "3. Comprehensive assessment approaches, including unbiased genome-wide assays, are being implemented to evaluate CRISPR-Cas associated off-targets and mitigate risks in clinical settings (source: Frontiers in Bioengineering and Biotechnology).\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Off-target effects in CRISPR/Cas9 gene editing - PMC\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10034092/\"},\n",
            "  {\"title\": \"Off-target effects in CRISPR-Cas genome editing for human ...\", \"url\": \"https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(25)00190-8\"},\n",
            "  {\"title\": \"Beyond the promise: evaluating and mitigating off-target effects in ...\", \"url\": \"https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1339189/full\"}\n",
            "]\n",
            "\n",
            "=== Persona: Medical Researcher ===\n",
            "[Medical Researcher Asker] What are the most recent advancements in CRISPR technology for therapeutic applications?\n",
            "[Expert] Recent advancements in CRISPR technology for therapeutic applications include:\n",
            "\n",
            "- Expansion of CRISPR-based gene editing in clinical trials, with a notable shift in the CRISPR medicine landscape as of 2024. These trials are exploring treatments for a range of diseases, including genetic disorders and cancers, and are increasingly focused on improving safety and efficacy (see Innovative Genomics, 2024).\n",
            "- Development of CRISPR screens to identify new therapeutic targets, which is opening promising avenues for novel treatments. This includes the use of CRISPR/Cas9 for precise genome editing and the identification of genes involved in disease pathways (see Molecular Cancer, 2024).\n",
            "- Progress in applying CRISPR/Cas9 technology to cancer immunotherapy, though challenges remain in clinical translation, such as delivery methods and minimizing off-target effects (see EHO Online, 2024).\n",
            "\n",
            "These advancements reflect a rapidly evolving field, with ongoing research aimed at overcoming current obstacles and expanding therapeutic potential.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR Clinical Trials: A 2024 Update - Innovative Genomics\", \"url\": \"https://innovativegenomics.org/news/crispr-clinical-trials-2024/\"},\n",
            "  {\"title\": \"Comprehensive review of CRISPR-based gene editing\", \"url\": \"https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01925-5\"},\n",
            "  {\"title\": \"CRISPR/Cas9 technology for advancements in cancer\", \"url\": \"https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00570-y\"}\n",
            "]\n",
            "[Medical Researcher Asker] What specific diseases are currently being targeted in the latest CRISPR clinical trials?\n",
            "[Expert] Recent CRISPR clinical trials are primarily targeting blood disorders (especially sickle cell disease), cardiovascular diseases, various cancers, and infectious diseases such as HIV. There are also early-stage trials for type 1 diabetes (T1D). The field is rapidly expanding, with new trials starting for additional diseases.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR Clinical Trials: A 2024 Update - Innovative Genomics\", \"url\": \"https://innovativegenomics.org/news/crispr-clinical-trials-2024/\"},\n",
            "  {\"title\": \"Overview CRISPR Clinical Trials 2025 - Learn | Innovate | Access\", \"url\": \"https://crisprmedicinenews.com/clinical-trials/\"},\n",
            "  {\"title\": \"Future of CRISPR: Tech Heralds Landmark Clinical Trials\", \"url\": \"https://www.infectiousdiseaseadvisor.com/features/future-of-crispr/\"}\n",
            "]\n",
            "[Medical Researcher Asker] What are the main challenges and ethical considerations associated with the use of CRISPR in clinical trials?\n",
            "[Expert] The main challenges and ethical considerations associated with the use of CRISPR in clinical trials include:\n",
            "\n",
            "1. Informed Consent and Risk: Ensuring that participants are fully informed about the risks involved in CRISPR-based interventions is a major ethical concern. The technology is still new, and long-term effects are not fully understood, making risk assessment challenging.\n",
            "\n",
            "2. Off-target Effects and Safety: CRISPR can cause unintended genetic changes (off-target effects), which may lead to harmful consequences. Ensuring the safety and precision of gene editing is a significant technical and ethical challenge.\n",
            "\n",
            "3. Germline Editing and Societal Impact: Editing genes in embryos or germline cells raises concerns about heritable changes, which could affect future generations. This brings up questions about consent from those future individuals and broader societal implications.\n",
            "\n",
            "4. Equity and Access: There are concerns about equitable access to CRISPR therapies and the potential for exacerbating social inequalities if such treatments are only available to certain groups.\n",
            "\n",
            "5. Moral and Regulatory Oversight: There is ongoing debate about the extent to which CRISPR should be used in clinical and pre-clinical research, and the need for robust regulatory frameworks to guide its ethical application.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Bioethical issues in genome editing by CRISPR-Cas9 technology\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC7129066/\"},\n",
            "  {\"title\": \"CRISPR ethics: moral considerations for applications of a powerful technology\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6286228/\"},\n",
            "  {\"title\": \"What are the Ethical Concerns of Genome Editing?\", \"url\": \"https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns\"}\n",
            "]\n",
            "[Medical Researcher Asker] What regulatory frameworks are in place to oversee the use of CRISPR in clinical research?\n",
            "[Expert] The use of CRISPR in clinical research is overseen by several regulatory frameworks, primarily in the US and internationally:\n",
            "\n",
            "1. In the US, the Food and Drug Administration (FDA) regulates CRISPR-based therapies as advanced therapy medicinal products. Clinical trials must comply with FDA requirements, including Investigational New Drug (IND) applications and adherence to guidelines for gene therapy products. The National Institutes of Health (NIH) also provides guidelines for research involving recombinant or synthetic nucleic acid molecules, which include CRISPR (see NIH Guidelines). Institutional Biosafety Committees (IBCs) and oversight mechanisms are also involved in ensuring compliance and safety in clinical research settings.\n",
            "\n",
            "2. Internationally, regulatory frameworks vary, but most countries require rigorous review and approval processes for gene-editing clinical trials, often modeled after or coordinated with US and European standards.\n",
            "\n",
            "3. Oversight includes ethical review, biosafety assessments, and ongoing monitoring to ensure patient safety and compliance with evolving guidelines.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Regulatory Considerations for Clinical Trial Applications with CRISPR\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/35452274/\"},\n",
            "  {\"title\": \"NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules\", \"url\": \"https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf\"},\n",
            "  {\"title\": \"Oversight of Human Genome Editing and Overarching Principles for Clinical Trials\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK447266/\"}\n",
            "]\n",
            "[Medical Researcher Asker] What are the key differences in CRISPR regulation between the US and other countries?\n",
            "[Expert] Key differences in CRISPR regulation between the US and other countries include:\n",
            "\n",
            "- The US generally has a more permissive and product-based regulatory approach, especially for CRISPR-edited crops, compared to many other countries. In the US, if a CRISPR-edited organism does not contain foreign DNA, it may not be regulated as a GMO, whereas the EU and other regions often regulate all gene-edited organisms as GMOs regardless of the method or final product.\n",
            "- In human genome editing, the US prohibits federal funding for research involving the editing of human embryos, but private funding is less restricted. Other countries, especially in Europe, have stricter legal bans or comprehensive regulatory frameworks that limit or prohibit such research.\n",
            "- Regulatory frameworks and societal concerns vary widely, with some countries allowing more research and commercialization, while others impose significant restrictions or outright bans.\n",
            "\n",
            "These differences impact research, commercialization, and international collaboration in CRISPR technologies.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"GMOs or non-GMOs? The CRISPR Conundrum - PMC\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10591184/\"},\n",
            "  {\"title\": \"Oversight of Human Genome Editing and Overarching Principles for ...\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK447266/\"},\n",
            "  {\"title\": \"CRISPR & Ethics - Innovative Genomics Institute (IGI)\", \"url\": \"https://innovativegenomics.org/crisprpedia/crispr-ethics/\"}\n",
            "]\n",
            "\n",
            "=== Persona: Agricultural Scientist ===\n",
            "[Agricultural Scientist Asker] What specific crops or agricultural practices are currently being enhanced using CRISPR technology?\n",
            "[Expert] CRISPR technology is currently being used to enhance a variety of crops and agricultural practices. Specific crops improved with CRISPR include grain crops, oilseed mustard, and others, with traits such as nutrition, pest resistance, and climate resilience being targeted. CRISPR is also being applied to improve crop quality, yield, and disease resistance, and to address challenges posed by climate change. These advancements are documented in recent scientific reviews and research articles.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Application of CRISPR/Cas9 in Crop Quality Improvement - PMC\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8073294/\"},\n",
            "  {\"title\": \"CRISPR-Cas9 genome editing in crop breeding for climate change ...\", \"url\": \"https://www.sciencedirect.com/science/article/pii/S2666154324001698\"},\n",
            "  {\"title\": \"Recent advances of CRISPR-based genome editing for enhancing ...\", \"url\": \"https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2024.1478398/full\"}\n",
            "]\n",
            "[Agricultural Scientist Asker] What are the regulatory challenges faced by CRISPR-enhanced crops in different countries?\n",
            "[Expert] CRISPR-enhanced crops face diverse regulatory challenges across countries:\n",
            "\n",
            "- In the United States, CRISPR-edited crops are generally regulated similarly to conventionally bred crops if they do not contain foreign DNA. The regulatory approach is product-based, focusing on the final characteristics rather than the process used (\"Food produced using new breeding techniques (NBTs), including CRISPR gene editing, are held to similar standards as conventional foods.\" - Genetic Literacy Project).\n",
            "\n",
            "- In the European Union, the regulatory environment is much stricter. The EU treats CRISPR-edited crops as genetically modified organisms (GMOs), subjecting them to the same rigorous approval processes as traditional GMOs, regardless of whether foreign DNA is present (\"some countries in the EU have, for instance, that plant gene editing using CRISPR-Cas cannot be considered by GMO. The German authorities judged...\" - Taylor & Francis; \"the US and EU ... have different opinions on the regulatory status of these crops.\" - Frontiers).\n",
            "\n",
            "- China is a major player in CRISPR patent applications and is developing its own regulatory framework, but details on implementation and enforcement are still emerging (\"Being completely dominant when it comes to CRISPR/Cas and other patent applications, China is...\" - Wiley).\n",
            "\n",
            "These differences create significant challenges for international trade and harmonization of standards.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"United States: Crops / Food - Global Gene Editing Regulation Tracker\", \"url\": \"https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-crops-food/\"},\n",
            "  {\"title\": \"GMOs or non-GMOs? The CRISPR Conundrum - Frontiers\", \"url\": \"https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2023.1232938/full\"},\n",
            "  {\"title\": \"A comparison of the EU regulatory approach to directed ...\", \"url\": \"https://nph.onlinelibrary.wiley.com/doi/10.1111/nph.15627\"}\n",
            "]\n",
            "[Agricultural Scientist Asker] What are the potential benefits of CRISPR technology for crop resilience against climate change?\n",
            "[Expert] CRISPR technology offers several potential benefits for improving crop resilience against climate change:\n",
            "\n",
            "1. Enhanced tolerance to abiotic stresses: CRISPR has been used to develop crops with improved resistance to drought and other extreme environmental conditions, helping them adapt to changing climates (Innovative Genomics Institute; Frontiers in Genome Editing).\n",
            "2. Improved disease resistance: By editing genes related to plant immunity, CRISPR can help crops better withstand diseases that are expected to become more prevalent with climate change (Genome Biology).\n",
            "3. Targeted breeding for resilience: CRISPR enables precise genetic modifications in major crops like wheat, maize, and rice, accelerating the development of varieties that can thrive under climate-induced stresses (ScienceDirect).\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR in Agriculture - Innovative Genomics Institute (IGI)\", \"url\": \"https://innovativegenomics.org/crisprpedia/crispr-in-agriculture/\"},\n",
            "  {\"title\": \"CRISPR/Cas9: a sustainable technology to enhance climate resilience in major Staple Crops\", \"url\": \"https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2025.1533197/full\"},\n",
            "  {\"title\": \"Engineering crops of the future: CRISPR approaches to develop...\", \"url\": \"https://genomebiology.biomedcentral.com/articles/10.1186/s13059-020-02204-y\"}\n",
            "]\n",
            "[Agricultural Scientist Asker] What are the long-term ecological impacts of introducing CRISPR-modified crops into existing agricultural systems?\n",
            "[Expert] Current research highlights several potential long-term ecological impacts of introducing CRISPR-modified crops into agricultural systems:\n",
            "\n",
            "1. Biosafety and Environmental Risks: There are concerns about unintended effects on non-target organisms and the broader ecosystem. Long-term safety implications require ongoing environmental monitoring and risk management, as the ecological consequences may not be immediately apparent (see PMC10671001).\n",
            "\n",
            "2. Genetic Diversity: The introduction of CRISPR crops could affect genetic diversity within crop species, which is crucial for long-term resilience to pests, diseases, and climate change. Reduced diversity may make crops more vulnerable to future threats (see Innovative Genomics Institute).\n",
            "\n",
            "3. Interactions with Existing Species: The interactions between CRISPR-modified crops and wild relatives or other organisms in the ecosystem are not fully understood. There is a need for comprehensive risk assessments to evaluate potential long-term effects, including gene flow and ecological balance (see Environmental Sciences Europe).\n",
            "\n",
            "Overall, while CRISPR offers precise gene editing, the long-term ecological impacts remain uncertain and require careful, ongoing study and monitoring.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR Variants for Gene Editing in Plants: Biosafety Risks and ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10671001/\"},\n",
            "  {\"title\": \"CRISPR & Ethics - Innovative Genomics Institute (IGI)\", \"url\": \"https://innovativegenomics.org/crisprpedia/crispr-ethics/\"},\n",
            "  {\"title\": \"The need for assessment of risks arising from interactions between ...\", \"url\": \"https://enveurope.springeropen.com/articles/10.1186/s12302-023-00734-3\"}\n",
            "]\n",
            "[Agricultural Scientist Asker] What strategies are being developed to mitigate the ecological risks associated with CRISPR-modified crops?\n",
            "[Expert] Recent strategies to mitigate the ecological risks of CRISPR-modified crops focus on comprehensive risk assessment and management. These include:\n",
            "\n",
            "- Understanding and evaluating the potential ecosystem impacts before release, which informs the design of risk management strategies to minimize unintended environmental effects (see PMC10671001).\n",
            "- Applying existing regulatory frameworks for environmental risk assessment, which consider cultivation, management, and harvesting techniques to reduce ecological risks (see NBK424533).\n",
            "- Integrating multiple pest management tactics and monitoring to ensure environmental safety and risk reduction, especially for insect-resistant crops (see ARSUserFiles/4056).\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR Variants for Gene Editing in Plants: Biosafety Risks and ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10671001/\"},\n",
            "  {\"title\": \"Regulation of Current and Future Genetically Engineered Crops ...\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK424533/\"},\n",
            "  {\"title\": \"The role and use of genetically engineered insect-resistant crops in ...\", \"url\": \"https://www.ars.usda.gov/ARSUserFiles/4056/BDS_Integrated%20management%20of%20insect%20pests%20Current%20and%20future%20developments%20-%20Vol%201_Chapter%2010_First%20proof_correct_SEN.pdf\"}\n",
            "]\n",
            "\n",
            "=== Persona: Bioethicist ===\n",
            "[Bioethicist Asker] What are the primary ethical concerns surrounding the use of CRISPR technology in human germline editing?\n",
            "[Expert] The primary ethical concerns surrounding the use of CRISPR technology in human germline editing include:\n",
            "\n",
            "1. Heritability and consent: Changes made to the germline are passed down to future generations, raising concerns about making irreversible decisions for individuals who cannot consent (future children and descendants).\n",
            "2. Safety and unintended consequences: There is limited understanding of human development, and editing the germline could have unpredictable, long-term effects that may not be immediately apparent.\n",
            "3. Appropriate use and societal impact: There are questions about what constitutes acceptable uses of germline editing (e.g., preventing disease vs. enhancement), and concerns about exacerbating social inequalities or enabling eugenics.\n",
            "\n",
            "These concerns are widely discussed in scientific and policy literature.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"What are the Ethical Concerns of Genome Editing?\", \"url\": \"https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns\"},\n",
            "  {\"title\": \"The Ethics of Germline Gene Editing - PMC\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5573992/\"},\n",
            "  {\"title\": \"CRISPR & Ethics - Innovative Genomics Institute (IGI)\", \"url\": \"https://innovativegenomics.org/crisprpedia/crispr-ethics/\"}\n",
            "]\n",
            "[Bioethicist Asker] What measures can be implemented to ensure ethical oversight in CRISPR research and applications, particularly in human germline editing?\n",
            "[Expert] To ensure ethical oversight in CRISPR research and especially in human germline editing, several measures are recommended:\n",
            "\n",
            "1. Establish robust governance frameworks at national and international levels, as outlined by the World Health Organization, to address ethical issues and ensure responsible research and application (see WHO framework).\n",
            "2. Require research ethics oversight boards to review and monitor all projects involving human germline editing, ensuring compliance with ethical standards and societal values.\n",
            "3. Implement independent, case-by-case ethical review mechanisms, reflecting the diversity and pluralism of global perspectives, as discussed in international summits and scholarly reviews.\n",
            "\n",
            "These measures help ensure transparency, accountability, and public trust in CRISPR research and its applications.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Human genome editing: a framework for governance\", \"url\": \"https://www.who.int/publications/i/item/9789240030060\"},\n",
            "  {\"title\": \"Oversight of Human Genome Editing and Overarching Principles for...\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK447266/\"},\n",
            "  {\"title\": \"Third International Summit on Human Genome Editing - NCBI...\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK593530/\"}\n",
            "]\n",
            "[Bioethicist Asker] What role do public perceptions and societal values play in shaping the ethical guidelines for CRISPR research and human germline editing?\n",
            "[Expert] Public perceptions and societal values play a significant role in shaping the ethical guidelines and governance of CRISPR research and human germline editing. According to academic and policy sources, public opinion alone is not sufficient to establish ethical policy, but it is crucial for building principles that guide responsible research (see PMC6791475). Societal values, including moral and hereditary concerns, influence attitudes toward gene editing, especially in applications related to human health and research (see Frontiersin.org). Furthermore, anticipatory governance frameworks emphasize the importance of public engagement and participation in decision-making processes, ensuring that diverse perspectives and values are integrated into regulatory and ethical guidelines (see tandfonline.com and PMC8916747).\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Societal and Ethical Impacts of Germline Genome Editing: How Can We Secure Public Engagement?\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6791475/\"},\n",
            "  {\"title\": \"Predicting Public Attitudes Toward Gene Editing of Human, Animal, and Plant Genomes\", \"url\": \"https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00704/full\"},\n",
            "  {\"title\": \"Toward anticipatory governance of human genome editing: a critical review of public engagement mechanisms\", \"url\": \"https://www.tandfonline.com/doi/full/10.1080/23299460.2021.1957579\"}\n",
            "]\n",
            "[Bioethicist Asker] What specific frameworks or models exist for integrating public opinion into the ethical governance of CRISPR technology?\n",
            "[Expert] Several frameworks and models exist for integrating public opinion into the ethical governance of CRISPR technology:\n",
            "\n",
            "1. The National Academies of Sciences, Engineering, and Medicine (NASEM) emphasizes broad public dialogue and engagement as essential for the governance of human genome editing, including CRISPR. Their reports advocate for structured public engagement to inform policy and ethical standards (see NAP, NCBI Bookshelf).\n",
            "\n",
            "2. Models of public engagement have shifted from \"knowledge deficit\" approaches (where experts simply inform the public) to more deliberative and anticipatory models. These models involve the public in ongoing discussions and decision-making processes about the ethical and technical aspects of CRISPR governance (see NCBI Bookshelf, OUP).\n",
            "\n",
            "3. Specific frameworks, such as those discussed in The CRISPR Journal and by the NASEM, recommend integrating public values and perspectives through structured forums, surveys, and participatory deliberation to shape governance frameworks and policy decisions.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"7 Public Engagement | Human Genome Editing: Science, Ethics ...\", \"url\": \"https://nap.nationalacademies.org/read/24623/chapter/9\"},\n",
            "  {\"title\": \"Public Engagement - Human Genome Editing - NCBI Bookshelf\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK447279/\"},\n",
            "  {\"title\": \"Governing with public engagement: an anticipatory approach to ...\", \"url\": \"https://academic.oup.com/spp/article/51/4/680/7634728\"}\n",
            "]\n",
            "[Bioethicist Asker] What strategies can be employed to effectively facilitate public dialogue and engagement on the ethical implications of CRISPR technology?\n",
            "[Expert] Effective strategies to facilitate public dialogue and engagement on the ethical implications of CRISPR technology include:\n",
            "\n",
            "1. Strategic Communication: Employing clear, accessible communication techniques tailored to diverse audiences helps demystify CRISPR and its ethical challenges, fostering informed discussion (see PubMed).\n",
            "2. Robust Stakeholder Engagement: Involving a broad range of stakeholdersâincluding affected communities, scientists, ethicists, and policymakersâensures diverse perspectives are considered, especially for technologies with wide societal impact (see Malaria Journal).\n",
            "3. International Summits and Forums: Hosting public events and international summits provides platforms for open dialogue, education, and consensus-building on governance and ethical issues (see ASU News).\n",
            "\n",
            "These approaches help build trust, transparency, and shared understanding around the ethical dimensions of CRISPR.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Communicating CRISPR: Challenges and opportunities in engaging ...\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/35168742/\"},\n",
            "  {\"title\": \"Articulating ethical principles guiding Target Malaria's engagement ...\", \"url\": \"https://malariajournal.biomedcentral.com/articles/10.1186/s12936-022-04062-4\"},\n",
            "  {\"title\": \"ASU to co-host international summit on genome editing | ASU News\", \"url\": \"https://news.asu.edu/20250520-science-and-technology-asu-cohost-international-summit-genome-editing\"}\n",
            "]\n",
            "\n",
            "=== Persona: Regulatory Policy Expert ===\n",
            "[Regulatory Policy Expert Asker] What are the current regulatory frameworks governing the use of CRISPR technology in human gene editing across different countries?\n",
            "[Expert] Many countries explicitly prohibit human heritable genome editing, and no country has officially endorsed this type of intervention. Regulatory frameworks vary: some countries have strict laws banning germline editing, while others have regulatory gaps or evolving policies. For example, Mexico is considering amendments to its framework, and African countries have diverse approaches. Global trackers and reviews highlight significant differences and ongoing debates about harmonizing regulations to prevent divergent standards.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Regulatory framework of human germline and heritable genome ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12069028/\"},\n",
            "  {\"title\": \"Global Gene Editing Regulation Tracker and Index\", \"url\": \"https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/\"},\n",
            "  {\"title\": \"Editing the Human Genome | The Regulatory Review\", \"url\": \"https://www.theregreview.org/2024/06/01/editing-the-human-genome/\"}\n",
            "]\n",
            "[Regulatory Policy Expert Asker] What are the key ethical considerations influencing the regulatory policies on human heritable genome editing in various countries?\n",
            "[Expert] Key ethical considerations influencing regulatory policies on human heritable genome editing include:\n",
            "\n",
            "1. Germline transmission: Ethical debates focus on the fact that changes made to the human germline are heritable and will be passed to future generations, raising concerns about unintended long-term consequences and the rights of future individuals.\n",
            "2. Safety and risk: There is significant concern about the safety and potential off-target effects of genome editing, which could result in unforeseen health issues.\n",
            "3. Social justice and equity: Policymakers consider the risk of exacerbating social inequalities if access to genome editing is limited to certain groups, or if it is used for non-therapeutic enhancements.\n",
            "4. Consent and autonomy: The inability of future generations to consent to genetic changes made today is a major ethical issue.\n",
            "5. Societal impact: Broader societal implications, such as the potential for eugenics or changing perceptions of disability and normalcy, are also central to regulatory discussions.\n",
            "\n",
            "These considerations shape diverse regulatory approaches worldwide, with some countries imposing strict bans and others allowing limited research under stringent oversight.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"What are the Ethical Concerns of Genome Editing?\", \"url\": \"https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns\"},\n",
            "  {\"title\": \"Beyond safety: mapping the ethical debate on heritable genome ...\", \"url\": \"https://www.nature.com/articles/s41599-022-01147-y\"},\n",
            "  {\"title\": \"Regulatory framework of human germline and heritable genome ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12069028/\"}\n",
            "]\n",
            "[Regulatory Policy Expert Asker] What specific measures are being proposed or implemented to address the ethical concerns related to germline transmission in CRISPR research and applications?\n",
            "[Expert] Several specific measures are being proposed and implemented to address ethical concerns related to germline transmission in CRISPR research:\n",
            "\n",
            "1. International frameworks, such as the WHOâs governance framework, outline values and principles for oversight, emphasizing transparency, public engagement, and risk assessment before any germline editing is considered.\n",
            "2. National regulations are being strengthened. For example, China introduced new ethical guidelines and stricter rules after the gene-editing scandal involving CRISPR-edited babies, requiring more rigorous ethical review and government approval for any germline editing research.\n",
            "3. Ethical assessment is increasingly required in research proposals, with a focus on long-term monitoring, informed consent, and limiting germline editing to cases where no reasonable alternatives exist.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Human genome editing: a framework for governance\", \"url\": \"https://www.who.int/publications/i/item/9789240030060\"},\n",
            "  {\"title\": \"China's New Ethical Guidelines for Human Genome Editing Research\", \"url\": \"https://www.china-briefing.com/news/chinas-new-ethical-guidelines-for-human-genome-editing-research/\"},\n",
            "  {\"title\": \"Bioethical issues in genome editing by CRISPR-Cas9 technology ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC7129066/\"}\n",
            "]\n",
            "[Regulatory Policy Expert Asker] What role do public engagement and stakeholder input play in shaping the regulatory policies for CRISPR technology?\n",
            "[Expert] Public engagement and stakeholder input play a significant role in shaping regulatory policies for CRISPR technology. These processes help ensure that ethical, social, and public concerns are considered in governance decisions. Broad public dialogue is seen as essential, especially given the ethical and societal implications of genome editing. Stakeholder engagement can guide policy by highlighting diverse perspectives and values, which is particularly important for controversial applications like heritable human genome editing. Effective engagement can also build public trust and legitimacy for regulatory frameworks.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Why Include the Public in Genome Editing Governance Deliberation ...\", \"url\": \"https://journalofethics.ama-assn.org/article/why-include-public-genome-editing-governance-deliberation/2019-12\"},\n",
            "  {\"title\": \"Public Engagement - Human Genome Editing - NCBI Bookshelf\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK447279/\"},\n",
            "  {\"title\": \"Public and Stakeholder Engagement in Developing ... - Frontiers\", \"url\": \"https://www.frontiersin.org/journals/political-science/articles/10.3389/fpos.2021.730869/full\"}\n",
            "]\n",
            "[Regulatory Policy Expert Asker] What are the potential consequences of failing to incorporate public engagement in the regulatory processes for CRISPR technology?\n",
            "[Expert] Failing to incorporate public engagement in the regulatory processes for CRISPR technology can have several significant consequences:\n",
            "\n",
            "1. Ethical and Sociopolitical Risks: Without public input, regulatory decisions may overlook important ethical, cultural, and societal concerns, potentially leading to public distrust and resistance (see NCBI Bookshelf, Issues in Science and Technology).\n",
            "2. Legitimacy and Acceptance: Regulations developed without public engagement may lack legitimacy and broad acceptance, making implementation and compliance more difficult (see Issues in Science and Technology).\n",
            "3. Missed Perspectives: Excluding diverse public voices can result in regulations that do not reflect the values or needs of affected communities, increasing the risk of controversy or backlash (see NCBI Bookshelf, OUP).\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Public Engagement - Human Genome Editing - NCBI Bookshelf\", \"url\": \"https://www.ncbi.nlm.nih.gov/books/NBK447279/\"},\n",
            "  {\"title\": \"CRISPR Democracy: Gene Editing and the Need for Inclusive Deliberation\", \"url\": \"https://issues.org/crispr-democracy-gene-editing-inclusive-deliberation/\"},\n",
            "  {\"title\": \"Governing with public engagement: an anticipatory approach to...\", \"url\": \"https://academic.oup.com/spp/article/51/4/680/7634728\"}\n",
            "]\n",
            "\n",
            "=== Persona: Basic Fact Researcher ===\n",
            "[Basic Fact Researcher Asker] What are the primary applications of CRISPR technology in medicine and agriculture?\n",
            "[Expert] CRISPR technology has transformative applications in both medicine and agriculture:\n",
            "\n",
            "In medicine, CRISPR is primarily used for genome editing to treat genetic disorders, infectious diseases, cancer, and in regenerative medicine. Techniques such as ex vivo gene editing and base editing are being developed for more precise and reliable therapeutic interventions (see sources below).\n",
            "\n",
            "In agriculture, CRISPR is applied to improve crop quality, enhance resistance to diseases and environmental stresses, and accelerate crop breeding. It enables targeted modifications in plant genomes, supporting the development of crops better suited to climate change and food security needs.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"CRISPR Advancements for Human Health - PMC\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11057861/\"},\n",
            "  {\"title\": \"Application of CRISPR/Cas9 in Crop Quality Improvement - PMC\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8073294/\"},\n",
            "  {\"title\": \"Applications of CRISPRâCas in agriculture and plant biotechnology\", \"url\": \"https://www.nature.com/articles/s41580-020-00288-9\"}\n",
            "]\n",
            "[Basic Fact Researcher Asker] What are the ethical considerations surrounding the use of CRISPR technology in human gene editing?\n",
            "[Expert] The main ethical considerations surrounding the use of CRISPR technology in human gene editing include:\n",
            "\n",
            "1. Germline Editing: Editing the human germline (heritable DNA changes) raises concerns because these changes are passed to future generations, potentially affecting the human gene pool permanently. This raises questions about consent from future generations and the long-term societal impact.\n",
            "2. Safety and Unintended Consequences: There are significant concerns about unforeseen, undesirable effects and risks to human safety, as off-target edits could cause harm.\n",
            "3. Equity and Access: The technology could exacerbate social inequalities if only certain groups have access, or if it is used for non-therapeutic enhancements.\n",
            "4. Morality and Appropriate Use: There are debates about the morality of editing human embryos, and about distinguishing between therapeutic uses (treating disease) and enhancement (e.g., selecting traits).\n",
            "\n",
            "These issues are widely discussed by scientific and bioethics communities, emphasizing the need for careful regulation and public dialogue.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"What are the Ethical Concerns of Genome Editing?\", \"url\": \"https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns\"},\n",
            "  {\"title\": \"Ethical Issues Regarding CRISPR Mediated Genome Editing\", \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28879860/\"},\n",
            "  {\"title\": \"CRISPR & Ethics - Innovative Genomics Institute (IGI)\", \"url\": \"https://innovativegenomics.org/crisprpedia/crispr-ethics/\"}\n",
            "]\n",
            "[Basic Fact Researcher Asker] What regulatory frameworks exist globally to govern the use of CRISPR technology in human gene editing?\n",
            "[Expert] Globally, regulatory frameworks for CRISPR and human gene editing are evolving and vary by country. The World Health Organization (WHO) has published a governance framework to guide the safe and ethical use of human genome editing technologies, including CRISPR. This framework emphasizes transparency, oversight, and international cooperation. Additionally, there are global trackers and indexes that monitor each country's regulations regarding gene editing. The creation of CRISPR-edited babies in 2018 highlighted the urgent need for robust international regulations, prompting further development of governance structures.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Human genome editing: a framework for governance\", \"url\": \"https://www.who.int/publications/i/item/9789240030060\"},\n",
            "  {\"title\": \"Global Gene Editing Regulation Tracker and Index\", \"url\": \"https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/\"},\n",
            "  {\"title\": \"WHO lays out a framework to regulate human genome editing\", \"url\": \"https://frontlinegenomics.com/who-lays-out-a-framework-to-regulate-human-genome-editing/\"}\n",
            "]\n",
            "[Basic Fact Researcher Asker] What are the potential risks and unintended consequences associated with the use of CRISPR technology in gene editing?\n",
            "[Expert] CRISPR gene editing carries several potential risks and unintended consequences. Chief among these are unintended genome alterations, such as off-target mutations, where CRISPR edits DNA at unintended locations, potentially causing harmful genetic changes. Studies have shown that CRISPR can cause hundreds of unintended mutations, which may be missed if whole genome sequencing is not used to detect them. Other concerns include the risk of unintended effects on non-target genes and broader ethical and safety considerations, especially in clinical applications.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Unintended CRISPR-Cas9 editing outcomes: a review of the ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10182114/\"},\n",
            "  {\"title\": \"CRISPR Gene Editing Can Cause Hundreds of Unintended ...\", \"url\": \"https://www.cuimc.columbia.edu/news/crispr-gene-editing-can-cause-hundreds-unintended-mutations\"},\n",
            "  {\"title\": \"CRISPR & Ethics - Innovative Genomics Institute (IGI)\", \"url\": \"https://innovativegenomics.org/crisprpedia/crispr-ethics/\"}\n",
            "]\n",
            "[Basic Fact Researcher Asker] What measures are being developed to minimize off-target effects in CRISPR gene editing?\n",
            "[Expert] Several measures are being developed to minimize off-target effects in CRISPR gene editing:\n",
            "\n",
            "- Engineering high-fidelity Cas9 variants: Modified Cas9 proteins with improved specificity reduce unintended DNA cuts.\n",
            "- Using truncated single guide RNAs (sgRNAs): Shorter sgRNAs can enhance specificity and reduce off-target activity.\n",
            "- Employing paired Cas9 nickases: Using two Cas9 nickases that each make a single-strand cut requires both to bind nearby, increasing precision.\n",
            "- Advanced computational tools: These help design sgRNAs with minimal off-target potential and predict possible off-target sites.\n",
            "- Genome-wide profiling methods: Techniques like Digenome-seq are used to detect and monitor off-target events, allowing for further refinement of editing strategies.\n",
            "\n",
            "These approaches collectively improve the accuracy and safety of CRISPR-based genome editing.\n",
            "\n",
            "R: [\n",
            "  {\"title\": \"Recent Advancements in Reducing the Off-Target Effect of CRISPR ...\", \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10802171/\"},\n",
            "  {\"title\": \"Off-target effects in CRISPR/Cas9 gene editing - Frontiers\", \"url\": \"https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1143157/full\"},\n",
            "  {\"title\": \"How to monitor and minimize off-target events during genome editing\", \"url\": \"https://assets.thermofisher.com/TFS-Assets/BID/Reference-Materials/how-monitor-minimize-target-events-genome-editing-white-paper.pdf\"}\n",
            "]\n",
            "\n",
            "Done at 2025-08-24T01:54:41.543600Z\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/tmp/ipython-input-3874045033.py:144: DeprecationWarning: datetime.datetime.utcnow() is deprecated and scheduled for removal in a future version. Use timezone-aware objects to represent datetimes in UTC: datetime.datetime.now(datetime.UTC).\n",
            "  print(\"\\nDone at\", datetime.utcnow().isoformat() + \"Z\")\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "fsidXJ06yYbL"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}